Amerise Biosciences shareholders approve FY26 accounts, appoint Hines as CFO
- Amerise Biosciences approved FY26 financial statements and CFO appointment
- Albert Hines appointed as Wholetime Director and Chief Financial Officer
- 12,675,378 votes cast in favor with zero opposition across both resolutions
- Only 38 out of 33,533 registered shareholders participated in voting
- Promoter group did not vote as they had no interest in the resolutions
*this image is generated using AI for illustrative purposes only.
Amerise Biosciences Limited shareholders unanimously approved the audited financial statements for FY26 and the appointment of Albert Hines as Wholetime Director and Chief Financial Officer at its 41st Annual General Meeting.
The meeting was held on September 24, 2026, at the company's registered office in Ahmedabad. Voting results indicate that 12,675,378 votes were cast in favor of both resolutions, with zero votes against. This represents a turnout of approximately 19.19% of the total outstanding shares eligible to vote.
Resolution outcomes
Two ordinary resolutions were passed during the AGM. The first resolution pertained to the adoption of the audited financial statements for the financial year ended March 31, 2026, along with the reports of the Directors and Auditors. The second resolution authorized the appointment of Albert Hines (DIN: 10742692) as Wholetime Director and Chief Financial Officer.
In both cases, the promoter and promoter group did not cast any votes, as they were not interested in the agenda items. The voting was conducted through remote e-voting and poll at the meeting venue.
Voting participation details
The company had 33,533 shareholders on the record date. However, only a small fraction participated in the voting process. No promoter or promoter group members voted, and no institutional investors participated. All votes were cast by public non-institutional shareholders.
| Metric | Value |
|---|---|
| Total shareholders on record date | 33,533 |
| Shareholders present (in person/proxy) | 38 |
| Total shares outstanding | 66,069,000 |
| Total votes polled | 12,675,378 |
| Percentage of shares voted | 19.185% |
| Votes in favor | 12,675,378 |
| Votes against | 0 |
What the numbers show
A significant divergence exists between the total number of registered shareholders and the active voting base. While there were 33,533 shareholders on the record date, only 38 individuals participated in the meeting or voting process. This low participation rate, combined with the fact that 100% of the cast votes were in favor, suggests a lack of dissent or active engagement from the broader shareholder base regarding these routine governance matters.
Historical Stock Returns for Amerise Biosciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.25% | +2.60% | -4.82% | +21.54% | +19.70% | 0.0% |
How will Albert Hines' tenure as CFO influence Amerise Biosciences' capital allocation strategy and debt management in the upcoming fiscal year?
What specific corporate governance reforms might the company implement to address the critically low shareholder participation rate of 19.19%?
Will the absence of institutional investor voting pressure lead to changes in Amerise Biosciences' dividend policy or share buyback programs?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
